logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Heterozygous Familial Hypercholesterolemia Hefh

    Medications for Heterozygous Familial Hypercholesterolemia Hefh

    FiltersReset Filters
    20 results

    • atorvastatin calcium

      (Atorvastatin calcium)
      NIVAGEN PHARMACEUTICALS, INC.
      Usage: Atorvastatin calcium is indicated to reduce the risk of myocardial infarction, stroke, and angina in at-risk adults. It also lowers LDL cholesterol in adults with hyperlipidemia, heterozygous or homozygous familial hypercholesterolemia, and treats primary dysbetalipoproteinemia and hypertriglyceridemia as an adjunct to diet.

    • colesevelam hydrochloride

      (COLESEVELAM HYDROCHLORIDE)
      Amneal Pharmaceuticals of New York LLC
      Usage: Colesevelam hydrochloride tablets are indicated to reduce elevated LDL cholesterol in adults with primary hyperlipidemia and in boys/girls (10-17 years) with heterozygous familial hypercholesterolemia. Additionally, it is used to improve glycemic control in adults with type 2 diabetes mellitus, alongside diet and exercise.

    • colesevelam hydrochloride

      (colesevelam hydrochloride)
      Glenmark Pharmaceuticals Inc., USA
      Usage: Colesevelam hydrochloride tablets are indicated to reduce elevated LDL cholesterol in adults with primary hyperlipidemia and in boys/postmenarchal girls aged 10-17 with heterozygous familial hypercholesterolemia. Additionally, they improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise.

    • colesevelam hydrochloride

      (Colesevelam Hydrochloride)
      Glenmark Pharmaceuticals Inc.,USA
      Usage: Colesevelam hydrochloride is indicated as an adjunct to diet and exercise for reducing LDL cholesterol in adults with primary hyperlipidemia and in boys/girls aged 10-17 with heterozygous familial hypercholesterolemia. It also improves glycemic control in adults with type 2 diabetes mellitus. Not for type 1 diabetes or diabetic ketoacidosis.

    • crestor

      (Rosuvastatin)
      AstraZeneca Pharmaceuticals LP
      Usage: CRESTOR is indicated for reducing the risk of major cardiovascular events in adults at increased risk, as an adjunct to diet for lowering LDL cholesterol in various hyperlipidemias, and for treating primary dysbetalipoproteinemia and hypertriglyceridemia in adults. It is also used in pediatric patients with familial hypercholesterolemia.

    • fluvastatin sodium

      (Fluvastatin Sodium)
      Lannett Company, Inc.
      Usage: Fluvastatin sodium extended-release tablets are indicated for reducing the risk of coronary revascularization and slowing coronary atherosclerosis in adults with coronary heart disease. They also help lower LDL cholesterol in adults with primary hyperlipidemia and in pediatric patients aged 10 and older with heterozygous familial hypercholesterolemia.

    • lovastatin

      (lovastatin)
      Lupin Pharmaceuticals, Inc.
      Usage: Lovastatin is indicated for lowering total and LDL cholesterol levels as part of a treatment strategy in individuals with dyslipidemia at risk for atherosclerotic vascular disease, including those with coronary heart disease and hypercholesterolemia. It is also used for primary prevention of coronary heart disease in certain populations.

    • nexletol

      (Bempedoic Acid)
      Esperion Therapeutics, Inc.
      Usage: NEXLETOL is indicated for adults at risk of myocardial infarction and coronary revascularization who cannot take statins, and for reducing LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia, either as a standalone treatment or with other LDL-C lowering therapies.

    • repatha

      (Evolocumab)
      Amgen USA Inc.
      Usage: REPATHA is indicated for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease, and as an adjunct to diet and other therapies to lower LDL cholesterol in adults and pediatric patients (ages 10+) with primary hyperlipidemia, heterozygous, or homozygous familial hypercholesterolemia.

    • rosuvastatin calcium

      (Rosuvastatin Calcium)
      Shandong New Time Pharmaceutical Co., Ltd.
      Usage: Rosuvastatin is indicated for reducing cardiovascular risk in adults without coronary heart disease, lowering LDL-C in various hyperlipidemia types, treating familial hypercholesterolemia in children and adults, and addressing primary dysbetalipoproteinemia and hypertriglyceridemia as an adjunct to diet and other therapies.